Impact of Tumor Response and Response Duration on Survival Among Participants Receiving Pembrolizumab Plus Chemotherapy as First-Line Therapy for Non-Small-Cell Lung Cancer

Abstract Introduction Response Evaluation Criteria in Solid Tumors (RECIST) is the primary tool for assessing tumor response in solid tumors. Immunotherapy elicits unique response patterns, and assessment of their contribution to overall survival (OS) is of interest. We evaluated tumor size changes...

Descrizione completa

Dettagli Bibliografici

Autori principali:	Marina C. Garassino, Ying Cheng, Delvys Rodriguez-Abreu, Silvia Novello, Julien Mazieres, Andrew G. Robinson, Steven F. Powell, Balazs Halmos, Jhanelle E. Gray, Meihua Wang, Cong Chen, Jing Yang, Fabricio Souza, Paul Schwarzenberger, Luis Paz-Ares
Natura:	Artigo
Lingua:	Inglês
Pubblicazione:	Adis, Springer Healthcare 2025-06-01
Serie:	Oncology and Therapy
Soggetti:	Immunotherapy NSCLC Pembrolizumab RECIST Tumor response
Accesso online:	https://doi.org/10.1007/s40487-025-00350-6
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!